Another type of emerging cancer immunotherapy, i.e., immune checkpoint inhibitors (ICIs), which block the immune checkpoint molecules and reactivate immune response against cancer cells, experienced even more dramatic growth since the FDA approval of the PD-1/PD-L1 inhibitors pembrolizumab and nivolumab for treatment of melanoma in 2014 [54]. The gene discussed is CD274; the disease is cancer.